Last reviewed · How we verify
DNA HIVIS and MVA-CMDR — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
DNA HIVIS and MVA-CMDR (DNA HIVIS and MVA-CMDR) — Instituto Nacional de Saúde, Mozambique.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DNA HIVIS and MVA-CMDR TARGET | DNA HIVIS and MVA-CMDR | Instituto Nacional de Saúde, Mozambique | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DNA HIVIS and MVA-CMDR CI watch — RSS
- DNA HIVIS and MVA-CMDR CI watch — Atom
- DNA HIVIS and MVA-CMDR CI watch — JSON
- DNA HIVIS and MVA-CMDR alone — RSS
Cite this brief
Drug Landscape (2026). DNA HIVIS and MVA-CMDR — Competitive Intelligence Brief. https://druglandscape.com/ci/dna-hivis-and-mva-cmdr. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab